MT Combined With XKSA for Depressive Symptoms During COVID-19

Status Completed

Clinical Trial Summary

Social isolation related mental health problems have raised many concerns during the COVID-19 outbreaks. Mental health care for people in quarantined hotels is in urgent need, but concrete program is rarely reported. Morita therapy and acupressure have been identified as effective treatments for regulating mood and sleep. The study aimed to examine whether Morita therapy (MT) combined with Xingnao Kaiqiao self-administered acupressure (XKSA) could improve depressive, anxiety symptoms and sleep quality in isolated people with depressive symptoms.

Clinical Trial Description

The study will evaluate the efficacy and safety of Morita therapy (MT) combined with Xingnao Kaiqiao self-administered acupressure (XKSA) on ameliorating depressive, anxiety and insomnia symptoms in quarantined people with depressive symptoms by measuring changes in clinical ratings before and after all the treatments immediately. 59 participants will be randomized to receive self-administered acupressure combined with Morita therapy or Morita therapy monotherapy during the two weeks of clinical observation and quarantine in Shenzhen, China. Morita therapy (MT) comprised bed rest and light work. In the first week, the participants were instructed to stay in the room but not restrict themselves to the bed. In the second week, the therapist guided the participants to face or accept instead of deliberately eliminating negative emotions and somatic discomfort. Xingnao Kaiqiao self-administered acupressure (XKSA) protocol evolved based on the XK acupuncture techniques after consulting a Chinese medicine specialist. Other two traditional Chinese medicine experts reviewed and approved the protocol. The protocol comprised pressing nine acupoints including Baihui, Sishenchong, Shenmen, Neiguan, Hegu, Taichong, Jianjing, Shenshu, and Yuji. Changes in depressive symptoms from baseline to the end of the study will be measured by the Patient Health Questionnaire 9-item depression scale (PHQ-9). Changes in anxiety symptoms from baseline to the end of the study will be measured by the Generalized Anxiety Disorder 7-item (GAD-7). Changes in sleep quality from baseline to the end of the study will be measured by the Insomnia Severity Index (ISI). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05631145
Study type	Interventional
Source	Central South University
Contact
Status	Completed
Phase	N/A
Start date	May 3, 2020
Completion date	October 15, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04122482` - An Online Course for Improving Knowledge and Access to Mental Health Accommodations in Canadian Enterprises	N/A
Completed	`NCT04085861` - Mental Health in Dancers; an Intervention Study	N/A
Recruiting	`NCT06060210` - Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion	Phase 4
Active, not recruiting	`NCT04588883` - Strengthening Families Living With HIV in Kenya	N/A
Recruiting	`NCT06065787` - NeuroGlove Anxiety and Depression Study	N/A
Active, not recruiting	`NCT04583891` - Mobile Apps to Reduce Distress in Breast Cancer Survivors Using an Adaptive Design	N/A
Completed	`NCT05554042` - Kintsugi Voice Device Study
Not yet recruiting	`NCT06162624` - Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons	N/A
Not yet recruiting	`NCT06430853` - Psychobiological Interventions in Pregnancy	N/A
Completed	`NCT02954250` - Mindfulness Based Cognitive Therapy for Depression and Cognitive Inhibition in Suicide	Early Phase 1
Recruiting	`NCT05647499` - Evaluating the Back 2 School Program in a Norwegian Setting: A Multicenter Pilot Study	N/A
Completed	`NCT03980873` - Cognitive-Behavioral Therapy for Young Adult Lesbian, Gay and Bisexual: Transdiagnostic Minority Stress Approach	N/A
Completed	`NCT04422327` - The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome	Phase 1/Phase 2
Completed	`NCT05368155` - Chronic Pelvic Pain and Education Skills Training for Women Veterans	N/A
Completed	`NCT05455905` - Voice Biomarkers Predictive of Depression and Anxiety
Completed	`NCT03272516` - Mindfulness Based Cognitive Therapy (MBCT) for Primary Care Patients	N/A
Not yet recruiting	`NCT05493865` - Parent-Child Single-Session Growth Mindset Intervention on Adolescent Depression and Anxiety Problems	N/A
Not yet recruiting	`NCT06027047` - Breakthrough Anxiety and Sleep Evaluation Using Linked Devices and Smartphone Application Onar (BASEL)
Not yet recruiting	`NCT05535101` - Non-invasive Brain Stimulation in Patients With Methamphetamine Use Disorder	N/A
Recruiting	`NCT04418115` - Fatigue as a Late Effect in Breast Cancer Survivors - is Acupuncture a Treatment Option?	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.